RespiQ

RespiQ is a Dutch based startup founded in 2019 with the slogan "Smart breath testing for better health." The company is currently focusing on developing an AI-enhanced breath analysis sensor for real-time disease diagnosis and management. This innovative, non-invasive health monitoring solution aims to provide affordable and easy-to-use options for point-of-care and at-home usage. The recent milestone for RespiQ is the €4.00M grant investment received on 20 November 2023 from the European Innovation Council. This significant funding will likely accelerate the company's efforts in advancing its breakthrough technology, with the vision to eventually enable affordable full breath biopsy. This development would allow for the accurate identification of a comprehensive set of disease markers in the breath, distinguishing it as a unique and reliable method for testing a wide range of diseases, including metabolic disease, respiratory disease like COPD home monitoring, cancer, cardiovascular disease, inflammatory disease, and infectious disease. RespiQ operates within the Biotechnology industry and is headquartered in The Netherlands. With its focus on revolutionizing health monitoring through advanced breath analysis, RespiQ presents an intriguing investment opportunity in the rapidly evolving biotech landscape.